This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
by Zacks Equity Research
With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA
by Zacks Equity Research
The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.
The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical
by Zacks Equity Research
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog
Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News
by Ekta Bagri
Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider
by Zacks Equity Research
Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Biohaven Pharmaceutical (BHVN) This Earnings Season?
by Zacks Equity Research
Biohaven Pharmaceutical (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 7.32% and 18.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -45.41% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biohaven (BHVN) Migraine Drug Meets Study Goals in China
by Zacks Equity Research
Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Diversify Your Portfolio With a New Psychedelic Drug ETF
by Sweta Jaiswal, FRM
A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.
Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More
by Ekta Bagri
Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.
Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study
by Zacks Equity Research
Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data
by Zacks Equity Research
Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -7.79% and 1.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?